Test management

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

Bureau Veritas becomes the market leader in Consumer Products Services in Mexico through the acquisition of “ANCE S.A de C.V.”, a leader in the testing and certification services for Electrical and Electronics consumer products

Retrieved on: 
Thursday, February 22, 2024

ANCE S.A de C.V. is the Mexican leader for conformity assessment covering many segments including electrical and electronic products, household appliances, and lighting and wireless products.

Key Points: 
  • ANCE S.A de C.V. is the Mexican leader for conformity assessment covering many segments including electrical and electronic products, household appliances, and lighting and wireless products.
  • It positions Bureau Veritas Consumer Products Services as the market leader in Mexico.
  • Hinda Gharbi, Chief Executive Officer of Bureau Veritas, commented: “We are delighted to welcome ANCE S.A de C.V. to Bureau Veritas.
  • Jointly, we will offer comprehensive testing, certification and global market solutions that are truly unique in our industry.”

Prancer Enterprise Welcomes Giri Muthukrishnan as Chief Growth Officer

Retrieved on: 
Wednesday, February 14, 2024

SAN DIEGO, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Prancer Enterprise, a pioneer in Breach and Attack Simulation (BAS) and PTaaS ( Pentest as a Service), is thrilled to announce the appointment of Giri Muthukrishnan as its new Chief Growth Officer. With an illustrious career that spans many highly regulated enterprises such as the US Federal Reserve, JPMorganChase, BNY Mellon, and IBM, Giri brings a wealth of experience in driving strategic, large-scale cyber initiatives to his new role at Prancer.

Key Points: 
  • Prancer Enterprise, a pioneer in Breach and Attack Simulation (BAS) and PTaaS ( Pentest as a Service), is thrilled to announce the appointment of Giri Muthukrishnan as its new Chief Growth Officer.
  • SAN DIEGO, Feb. 14, 2024 /PRNewswire-PRWeb/ -- Prancer Enterprise, a pioneer in Breach and Attack Simulation (BAS) and PTaaS ( Pentest as a Service), is thrilled to announce the appointment of Giri Muthukrishnan as its new Chief Growth Officer.
  • "We are excited to welcome Giri Muthukrishnan to the Prancer team as Chief Growth Officer," said Farshid Mahdavipour, CEO of Prancer Enterprise.
  • With Giri Muthukrishnan at the helm of growth initiatives, the company is set to achieve new heights of success.

Children’s Hospital Los Angeles Unveils New Fetal Cardiac Clinic

Retrieved on: 
Tuesday, February 13, 2024

Children’s Hospital Los Angeles has opened its new Fetal Cardiac Clinic , a unique space for expectant mothers and the fetal patient population to continue receiving the highest level of comprehensive care during pregnancy, birth and beyond.

Key Points: 
  • Children’s Hospital Los Angeles has opened its new Fetal Cardiac Clinic , a unique space for expectant mothers and the fetal patient population to continue receiving the highest level of comprehensive care during pregnancy, birth and beyond.
  • View the full release here: https://www.businesswire.com/news/home/20240213588362/en/
    The Heart Institute at Children's Hospital Los Angeles celebrates the opening of its new Fetal Cardiac Clinic.
  • “With the launch of our new Fetal Cardiac Clinic, we now have a dedicated space that can serve as a one-stop shop for families in need of comprehensive prenatal diagnostic testing and counseling for cardiac anomalies.”
    CHLA’s state-of-the-art Fetal Cardiac Clinic features over 3,000 square feet of space and three scanning rooms dedicated to fetal cardiology.
  • Services provided at the CHLA Fetal Cardiac Clinic include:
    To learn more about CHLA’s Fetal Cardiac Clinic, visit CHLA.org/FetalCardiology or call 323-361-7398.

Alzheimer's Research & Therapy: Linus Health Digital Clock and Recall Test Detects Early Cognitive Impairment in Over 80% of Patients Who Were Misclassified in Commonly Used Paper-Based Test

Retrieved on: 
Tuesday, February 13, 2024

BOSTON, Feb. 13, 2024 /PRNewswire/ -- A proprietary cognitive assessment from Linus Health, a digital health company focused on enabling early detection of Alzheimer's and other dementias, outperforms the most commonly used paper-based assessment in detecting early mild cognitive impairment and dementia and with less ethnic and racial bias, according to a peer-reviewed study recently published in the prestigious medical journal Alzheimer's Research & Therapy.

Key Points: 
  • The body of research confirms the most recent findings that the DCR outperforms a commonly used traditional cognitive test, the MMSE, in detecting early signs of cognitive impairment, and is more accurate overall in classifying mild cognitive impairment and mild dementia.
  • More than 80% of Americans are unfamiliar with mild cognitive impairment, which can be an early stage of Alzheimer's Disease, according to the Alzheimer's Association.
  • Symptoms are also not always noticeable, leading to delayed screenings and potentially greater risk to patients' brain health.
  • In contrast, the DCR was able to detect cognitive impairment in more than 80% of those the MMSE misclassified.

Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing

Retrieved on: 
Wednesday, January 24, 2024

This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.

Key Points: 
  • This publication reports on the prenatal genetic disease clinical trial program to evaluate OGM as an alternative to SOC workflows.
  • This second interim readout is designed to evaluate endpoints connected to analytical performance using an expanded dataset in key areas of technical performance and clinical utility of OGM.
  • The study is an Institutional Review Board (IRB)-approved, multicenter, double-blinded trial with samples from 219 unique retrospective (57) and prospective (162) clinical research subjects.
  • All samples had been previously tested with traditional methods including karyotyping (KT), fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA).

Urology Care Foundation Announces Three New Additions to Board of Directors

Retrieved on: 
Tuesday, January 23, 2024

The Foundation's Board of Directors' governance structure includes public directors, AUA member urologists, the AUA's treasurer and the president.

Key Points: 
  • The Foundation's Board of Directors' governance structure includes public directors, AUA member urologists, the AUA's treasurer and the president.
  • We are excited to work with them to continue the Urology Care Foundation’s mission,” said Harris M. Nagler, MD, Urology Care Foundation president.
  • We welcome our new board members and look forward to working with them as the Urology Care Foundation continues to advance its mission and vision.
  • For more information on the Urology Care Foundation Board of Directors, visit: https://urologyhealth.org/about-us/leadership

MEDITWIN Brings Together French Science and Technology Excellence Around Virtual Twins for the Future of Medical Care

Retrieved on: 
Wednesday, January 24, 2024

MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.

Key Points: 
  • MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all.
  • The MEDITWIN project will offer personalized virtual twins of organs, metabolism and cancer, for better diagnosis and treatment.
  • Seven new medical practices will be developed from the virtual twins, in neurology, cardiology and oncology.
  • The MEDITWIN public-private alliance is a major step forward, mobilizing the best of medicine, science and technology to serve future healthcare.

Cincinnati Children's Elevates Care for Pregnant Women with Complex Fetal Conditions

Retrieved on: 
Friday, January 26, 2024

CINCINNATI, Jan. 26, 2024 /PRNewswire/ -- Cincinnati Children's announces the opening of a new antepartum unit within the Fetal Care Center .

Key Points: 
  • CINCINNATI, Jan. 26, 2024 /PRNewswire/ -- Cincinnati Children's announces the opening of a new antepartum unit within the Fetal Care Center .
  • "These rooms have been strategically placed in the hospital to provide pregnant women the best quality care and close proximity to any sophisticated fetal surgeries they may need leading up to birth," said Foong-Yen Lim, MD, Surgical Director, Cincinnati Children's Fetal Care Center.
  • The antepartum unit allows pregnant women to receive care needed to prolong their pregnancy, reducing risks and enhancing outcomes for their babies.
  • Differentiating itself from other fetal care clinics, Cincinnati Children's Fetal Care Center employs highly skilled nurses from TriHealth to provide compassionate, comforting care to expecting mothers before and after delivery.

New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath's pTau217 Test in Identifying Amyloid and Tau in the Brain

Retrieved on: 
Monday, January 22, 2024

CARLSBAD, Calif., Jan. 22, 2024 /PRNewswire/ -- ALZpath, Inc. (ALZpath), a leader in Alzheimer's diagnostics, announced new findings published online today in JAMA Neurology showing that its proprietary blood-based biomarker assay for phosphorylated tau at residue 217 (pTau217) delivers high diagnostic accuracy and consistency in identifying amyloid and tau in the brain. The article, "Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer's Disease Pathology," was authored by Dr. Nicholas Ashton and colleagues from the University of Gothenburg, Sweden.

Key Points: 
  • With the novel ALZpath pTau217 assay and test, ALZpath is transforming Alzheimer's disease diagnosis and monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide.
  • The ALZpath pTau217 assay showed high diagnostic accuracy in identifying elevated amyloid (AUC, 0.92-0.96; 95%CI 0.89-0.99) and tau (AUC, 0.93-0.97; 95%CI 0.84-0.99) in the brain across all cohorts.
  • Longitudinally, ALZpath's pTau217 test in blood showed an annual increase in individuals with amyloid plaques, with the highest increase observed in those who also had tau pathology.
  • The ALZpath pTau217 test will also be commercially available on other research and diagnostic platforms in support of global accessibility and scalability.